To this end, we selected a panel of genes previously reported to be deregulated in T2D patients [4] (CAPN10, CDK5, CDKN2A, IGF2BP2, KCNQ1, THADA, TSPAN8) and explored their mRNA levels in peripheral blood samples from AML- versus non-cancerous individuals utilizing RNAseq data and the TNMplot web tool [27]. This evidence concerns the gene CDKN2A and acute myeloid leukemia.